Reports Q1 revenue C$30.1M vs. $25.1M last year. “Our continued market share expansion in Q1 2026 reflects the strength of our brands and our disciplined approach to growth,” said Zohar Krivorot, CEO. “We achieved our highest quarterly national retail market share to-date this period, driven by improved supply availability and continued sell-through strength across our branded portfolio. With our post-processing capacity now fully utilized, our Fiscal 2026 investments prioritize the development of our new processing center at Valleyfield and the preparation of three additional grow zones, positioning Cannara to support future expansion while maintaining and improving operational efficiency.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LOVFF:
- Cannara Biotech Upgrades to OTCQX and Sets Dates for Q1 Results and Shareholder Meeting
- Cannara Biotech achieves OTCQX qualification
- OTC Markets welcomes Cannara Biotech to OTCQX
- Cannara Biotech Takes Top Market Share in Québec and Cleans Up Equity Compensation Plans
- Cannara Biotech provides update on Quebec vape category launch